IL98175A - 1-) 2-Naphthylethyl (-4-) 3-trifluoromethylphenyl (-1, 2, 3, 6-tetrahydropyridine for the treatment of brain and nerve diseases - Google Patents

1-) 2-Naphthylethyl (-4-) 3-trifluoromethylphenyl (-1, 2, 3, 6-tetrahydropyridine for the treatment of brain and nerve diseases

Info

Publication number
IL98175A
IL98175A IL9817591A IL9817591A IL98175A IL 98175 A IL98175 A IL 98175A IL 9817591 A IL9817591 A IL 9817591A IL 9817591 A IL9817591 A IL 9817591A IL 98175 A IL98175 A IL 98175A
Authority
IL
Israel
Prior art keywords
compound
neuronal
treatment
dementia
use according
Prior art date
Application number
IL9817591A
Other languages
English (en)
Hebrew (he)
Other versions
IL98175A0 (en
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Priority to IL11216791A priority Critical patent/IL112167A/en
Publication of IL98175A0 publication Critical patent/IL98175A0/xx
Priority to IL11216794A priority patent/IL112167A0/xx
Publication of IL98175A publication Critical patent/IL98175A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Neurosurgery (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Food Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL9817591A 1990-05-22 1991-05-17 1-) 2-Naphthylethyl (-4-) 3-trifluoromethylphenyl (-1, 2, 3, 6-tetrahydropyridine for the treatment of brain and nerve diseases IL98175A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
IL11216791A IL112167A (en) 1990-05-22 1991-05-17 Evaluation of compound activity in the nervous system
IL11216794A IL112167A0 (en) 1990-05-22 1994-12-27 Evaluation of neuronally active compounds

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9006399A FR2662355B1 (fr) 1990-05-22 1990-05-22 Utilisation de la 1-[2-(2-naphtyl)ethyl]-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine pour la preparation de medicaments destines au traitement de troubles cerebraux et neuronaux.

Publications (2)

Publication Number Publication Date
IL98175A0 IL98175A0 (en) 1992-06-21
IL98175A true IL98175A (en) 1996-01-19

Family

ID=9396855

Family Applications (3)

Application Number Title Priority Date Filing Date
IL11216791A IL112167A (en) 1990-05-22 1991-05-17 Evaluation of compound activity in the nervous system
IL9817591A IL98175A (en) 1990-05-22 1991-05-17 1-) 2-Naphthylethyl (-4-) 3-trifluoromethylphenyl (-1, 2, 3, 6-tetrahydropyridine for the treatment of brain and nerve diseases
IL11216794A IL112167A0 (en) 1990-05-22 1994-12-27 Evaluation of neuronally active compounds

Family Applications Before (1)

Application Number Title Priority Date Filing Date
IL11216791A IL112167A (en) 1990-05-22 1991-05-17 Evaluation of compound activity in the nervous system

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL11216794A IL112167A0 (en) 1990-05-22 1994-12-27 Evaluation of neuronally active compounds

Country Status (17)

Country Link
US (3) US5229389A (ja)
EP (2) EP0458696B1 (ja)
JP (2) JP2618115B2 (ja)
KR (1) KR0181330B1 (ja)
AT (2) ATE132369T1 (ja)
BR (1) BR9105015A (ja)
CA (2) CA2365832C (ja)
CY (1) CY2283B1 (ja)
DE (2) DE69115989T2 (ja)
DK (2) DK0458696T3 (ja)
FR (1) FR2662355B1 (ja)
HK (1) HK1001471A1 (ja)
HU (1) HU208922B (ja)
IE (1) IE911707A1 (ja)
IL (3) IL112167A (ja)
TW (1) TW216771B (ja)
ZA (1) ZA913865B (ja)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0192386A (ja) * 1987-10-05 1989-04-11 Hitachi Ltd 密閉循環型吸収式冷凍機及び吸収式冷凍機用吸収液
FR2662355B1 (fr) * 1990-05-22 1994-11-10 Sanofi Sa Utilisation de la 1-[2-(2-naphtyl)ethyl]-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine pour la preparation de medicaments destines au traitement de troubles cerebraux et neuronaux.
FR2662442A1 (fr) * 1990-05-23 1991-11-29 Midy Spa Trifluoromethylphenyltetrahydropyridines n-substituees procede pour leur preparation, intermediaires du procede et compositions pharmaceutiques les contenant.
US5618822A (en) * 1990-05-23 1997-04-08 Sanofi N-substituted trifluoromethylphenyltetrahydropyridines, process for the preparation thereof, intermediates in said process and pharmaceutical compositions containing them
US5557209A (en) * 1990-12-20 1996-09-17 Hewlett-Packard Company Identification of pin-open faults by capacitive coupling through the integrated circuit package
FR2690158B1 (fr) * 1992-04-17 1994-07-22 Sanofi Elf Nouveau derive arylpiperidinique, procede pour sa preparation et compositions pharmaceutiques le contenant.
FR2702656B1 (fr) * 1993-03-18 1995-06-16 Sanofi Elf Utilisation de derives de la tetrahydropyridine pour la preparation de medicaments cardioprotecteurs.
US5698565A (en) * 1995-06-09 1997-12-16 Hoffmann-La Roche Inc. Use of phenoxy-pyridine derivatives
FR2736053B1 (fr) * 1995-06-28 1997-09-19 Sanofi Sa Nouvelles 1-phenylalkyl-1,2,3,6-tetrahydropyridines
FR2740343B1 (fr) * 1995-10-26 1999-01-22 Sanofi Sa Utilisation de la 1-(2-napht-2-yl-ethyl)-4- (3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine pour la preparation de medicaments destines au traitement de la sclerose laterale amyotrophique
ATE200423T1 (de) * 1995-10-26 2001-04-15 Sanofi Synthelabo Verwendung von 1-(2-naphtylethyl)-4-(3- trifluoromethylphenyl)-1,2,3,6-tetrahydropyridi zur herstellung eines medikaments zur behandlung der amyotrophen lateralsklerode
AU719038B2 (en) * 1996-03-29 2000-05-04 Trustees Of Boston University Methods for diagnosing and treating Alzheimer's disease
US5891465A (en) * 1996-05-14 1999-04-06 Biozone Laboratories, Inc. Delivery of biologically active material in a liposomal formulation for administration into the mouth
FR2757160B1 (fr) * 1996-12-13 1999-03-12 Sanofi Sa 1-phenylalkyl-1,2,3,6-tetrahydropyridines
FR2757161B1 (fr) * 1996-12-13 1999-03-12 Sanofi Sa Diphenylalkyl-tetrahydropyridines
FR2757510B1 (fr) * 1996-12-23 2000-01-07 Sanofi Sa Forme microparticulaire d'un derive de tetrahydropyridine
FR2757512B1 (fr) * 1996-12-24 1999-03-12 Sanofi Sa Utilisation de benzoylalkyl-1-1,2,3,6-tetrahydropyridines
EE9900332A (et) * 1997-02-03 2000-02-15 Sanofi-Synthlabo 1-[4-(3-trifluorometüülfenüül)-1,2,3,6-tetrahüdropüriid-1-üül]-2-(6,7-dimetoksünaft-2- üül)etaani kasutamine neurotroopse toimega ravimite valmistamiseks
FR2762514B1 (fr) 1997-04-29 1999-10-22 Sanofi Sa Utilisation de derives de la tetrahydropyridine pour la preparation de medicaments pour le traitement des maladies entrainant une demyelinisation
FR2763847B1 (fr) 1997-05-28 2003-06-06 Sanofi Sa Utilisation de tetrahydropyridines 4-substituees pour fabriquer des medicaments agissant sur le tgf-beta-1
FR2771007B1 (fr) * 1997-11-14 2000-12-01 Sanofi Sa Association de principes actifs pour le traitement de la demence senile du type alzheimer
CO4980891A1 (es) * 1997-11-14 2000-11-27 Sanofi Sa Asociacion de principios activos para el tratamiento de la demencia senil de tipo azheimer
DE19751949A1 (de) 1997-11-24 1999-05-27 Bayer Ag Verwendung von substituierten Aminomethyl-Chromanen zur Verhinderung der neuronalen Degeneration und zur Förderung der neuronalen Regeneration
TWI237035B (en) * 1998-07-24 2005-08-01 Polyplastics Co Polyacetal copolymer
CN102727501A (zh) * 2002-03-27 2012-10-17 菲特法姆股份有限公司 皂角苷配基及其衍生物的用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2531707A1 (fr) * 1982-08-16 1984-02-17 Midy Spa Trifluoromethylphenyltetrahydropyridines substituees a activite anorexigene, un procede de preparation et compositions pharmaceutiques
FR2639226B1 (fr) * 1988-11-18 1993-11-05 Sanofi Utilisation de trifluoromethylphenyltetrahydropyridines pour la preparation de medicaments destines a combattre les troubles anxio-depressifs
FR2662355B1 (fr) * 1990-05-22 1994-11-10 Sanofi Sa Utilisation de la 1-[2-(2-naphtyl)ethyl]-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine pour la preparation de medicaments destines au traitement de troubles cerebraux et neuronaux.

Also Published As

Publication number Publication date
AU7713391A (en) 1991-11-28
TW216771B (ja) 1993-12-01
HK1001471A1 (en) 1998-06-19
IL112167A (en) 1996-01-31
DE69132797T2 (de) 2002-05-29
DK0458696T3 (da) 1996-05-20
CA2365832A1 (en) 1991-11-23
KR0181330B1 (ko) 1999-03-20
EP0458696B1 (fr) 1996-01-03
EP0458696A3 (en) 1992-03-18
JP2954029B2 (ja) 1999-09-27
DE69115989T2 (de) 1996-08-22
DE69115989D1 (de) 1996-02-15
HU911729D0 (en) 1991-12-30
DE69132797D1 (de) 2001-12-06
CY2283B1 (en) 2003-07-04
US5270320A (en) 1993-12-14
FR2662355B1 (fr) 1994-11-10
HUT59824A (en) 1992-07-28
ATE207747T1 (de) 2001-11-15
DK0655247T3 (da) 2002-02-18
ZA913865B (en) 1992-02-26
JPH04226917A (ja) 1992-08-17
EP0655247B1 (fr) 2001-10-31
IE20011078A1 (en) 2002-03-20
KR910019617A (ko) 1991-12-19
BR9105015A (pt) 1993-05-25
US5468753A (en) 1995-11-21
EP0458696A2 (fr) 1991-11-27
ATE132369T1 (de) 1996-01-15
JPH09132535A (ja) 1997-05-20
IL112167A0 (en) 1995-03-15
FR2662355A1 (fr) 1991-11-29
CA2042974C (en) 2002-09-17
HU208922B (en) 1994-02-28
AU636488B2 (en) 1993-04-29
US5229389A (en) 1993-07-20
CA2042974A1 (en) 1991-11-22
EP0655247A1 (fr) 1995-05-31
CA2365832C (en) 2007-08-07
IL98175A0 (en) 1992-06-21
JP2618115B2 (ja) 1997-06-11
IE911707A1 (en) 1991-12-04

Similar Documents

Publication Publication Date Title
US5229389A (en) Method for evaluating neuronal activity of a drug
IE83649B1 (en) Use of a 1-(2-naphthylethyl)-4-(3-trifluoromethylphenyl)-1,2,3,6- tetra-hydropyridine for the manufacture of a medicament for the treatment of cerebral and neuronal diseases
Levin et al. Nicotinic acetylcholine involvement in cognitive function in animals
Hadjiconstantinou et al. GM1 ganglioside: in vivo and in vitro trophic actions on central neurotransmitter systems
Kawai et al. Nicotinic acetylcholine receptors containing α7 subunits on rat cortical neurons do not undergo long‐lasting inactivation even when up‐regulated by chronic nicotine exposure
US6232326B1 (en) Treatment for schizophrenia and other dopamine system dysfunctions
Abdulla et al. Relationship between up-regulation of nicotine binding sites in rat brain and delayed cognitive enhancement observed after chronic or acute nicotinic receptor stimulation
Akaneya et al. Involvement of free radicals in MPP+ neurotoxicity against rat dopaminergic neurons in culture
SK15702000A3 (sk) Použitie
Taslim et al. Role of mouse cerebellar nicotinic acetylcholine receptor (nAChR) α4β2-and α7 subtypes in the behavioral cross-tolerance between nicotine and ethanol-induced ataxia
Liu et al. Conditioned place preference induced by licit drugs: establishment, extinction, and reinstatement
CN111655669A (zh) 治疗包括运动神经元疾病的神经紊乱的组合物和方法
Jonnala et al. Relative levels of cytoprotection produced by analogs of choline and the role of α7‐nicotinic acetylcholine receptors
Hulley et al. Inhibitors of type IV phosphodiesterases reduce the toxicity of MPTP in substantia nigra neurons in vivo
Charlton et al. Parkinson's disease-like effects of S-adenosyl-L-methionine: effects of L-dopa
EP0821954A1 (en) Method for treating mental retardation
Bäckman et al. Effects of transferrin receptor antibody-NGF conjugate on young and aged septal transplants in oculo
Dick et al. Investigation of the interaction between nitric oxide and vasoactive intestinal polypeptide in the guinea‐pig gastric fundus
US6319955B1 (en) Use of MEK1 inhibitors as protective agents against damage due to ischemia
Maragos et al. Inhibition of nitric oxide synthase activity attenuates striatal malonate lesions in rats
EP0821955B1 (en) Use of 3-(4-hexyloxy-1,2,5-thiadiazol-3-yl)-1,2,5,6-tetrahydro-1-methylpyridine (xanomeline) for treating bipolar disorder
Perry Cholinergic component of cognitive impairment in dementia
Poli et al. Spontaneous recovery of MPTP-damaged catecholamine systems in goldfish brain areas
Burr et al. Glucose intolerance and impaired insulin release following 6-hydroxydopamine administration to intact rats
HU211924A9 (hu) 1 -(2-NaftiI -étil)-4-(3-trifI uor-metil-fenil)-1,2,3,6-tetrahidropiridint tartalmazó, agyi és idegrendszeri megbetegedések kezelésére való gyógyszerkészítmények

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
HC Change of name of proprietor(s)
KB Patent renewed
KB Patent renewed
EXP Patent expired